JPWO2021102505A5 - - Google Patents

Info

Publication number

JPWO2021102505A5

JPWO2021102505A5 JP2022530318A JP2022530318A JPWO2021102505A5 JP WO2021102505 A5 JPWO2021102505 A5 JP WO2021102505A5 JP 2022530318 A JP2022530318 A JP 2022530318A JP 2022530318 A JP2022530318 A JP 2022530318A JP WO2021102505 A5 JPWO2021102505 A5 JP WO2021102505A5

Authority

JP

Japan

Prior art keywords

isolated

antibody

fragment

neisseria

immunogenic

Prior art date

2023-11-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000623 proteins and genes Proteins 0.000 claims description 42
• 239000012634 fragment Substances 0.000 claims description 40
• 230000002163 immunogen Effects 0.000 claims description 38
• 102000004169 proteins and genes Human genes 0.000 claims description 33
• 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 31
• 210000004027 cell Anatomy 0.000 claims description 29
• 241000588650 Neisseria meningitidis Species 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 21
• 238000000034 method Methods 0.000 claims description 19
• 102000039446 nucleic acids Human genes 0.000 claims description 19
• 108020004707 nucleic acids Proteins 0.000 claims description 19
• 150000007523 nucleic acids Chemical class 0.000 claims description 19
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 18
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 18
• 230000002401 inhibitory effect Effects 0.000 claims description 14
• 230000002068 genetic effect Effects 0.000 claims description 10
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
• 208000015181 infectious disease Diseases 0.000 claims description 8
• 230000036039 immunity Effects 0.000 claims description 7
• 230000001939 inductive effect Effects 0.000 claims description 7
• 239000012472 biological sample Substances 0.000 claims description 6
• 230000028993 immune response Effects 0.000 claims description 6
• 210000002966 serum Anatomy 0.000 claims description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
• 229960002897 heparin Drugs 0.000 claims description 4
• 229920000669 heparin Polymers 0.000 claims description 4
• 238000006467 substitution reaction Methods 0.000 claims description 4
• 238000004519 manufacturing process Methods 0.000 claims description 3
• 239000002773 nucleotide Substances 0.000 claims description 3
• 125000003729 nucleotide group Chemical group 0.000 claims description 3
• 241000894006 Bacteria Species 0.000 claims description 2
• 102220590966 Group 3 secretory phospholipase A2_S91T_mutation Human genes 0.000 claims description 2
• 241000588653 Neisseria Species 0.000 claims description 2
• 239000000427 antigen Substances 0.000 claims description 2
• 102000036639 antigens Human genes 0.000 claims description 2
• 108091007433 antigens Proteins 0.000 claims description 2
• 210000004900 c-terminal fragment Anatomy 0.000 claims description 2
• 102220346512 c.248T>C Human genes 0.000 claims description 2
• 102220366066 c.262C>T Human genes 0.000 claims description 2
• -1 carrier Substances 0.000 claims description 2
• 230000000295 complement effect Effects 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 102220261986 rs1044174795 Human genes 0.000 claims description 2
• 102220223852 rs1060502978 Human genes 0.000 claims description 2
• 102200061298 rs1064795967 Human genes 0.000 claims description 2
• 102220210880 rs201979180 Human genes 0.000 claims description 2
• 102220112531 rs2240308 Human genes 0.000 claims description 2
• 102200058025 rs28941782 Human genes 0.000 claims description 2
• 102200082931 rs33945546 Human genes 0.000 claims description 2
• 102200155464 rs397507509 Human genes 0.000 claims description 2
• 102200091336 rs587777472 Human genes 0.000 claims description 2
• 102200108208 rs756233241 Human genes 0.000 claims description 2
• 102200040542 rs80356524 Human genes 0.000 claims description 2
• 229960005486 vaccine Drugs 0.000 claims description 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 12
• 238000012258 culturing Methods 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 230000003053 immunization Effects 0.000 claims 1
• 238000002649 immunization Methods 0.000 claims 1
• 208000034762 Meningococcal Infections Diseases 0.000 description 3
• 206010018612 Gonorrhoea Diseases 0.000 description 2
• 208000001786 gonorrhea Diseases 0.000 description 2
• 102100030009 Azurocidin Human genes 0.000 description 1
• 101710154607 Azurocidin Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 108700007374 Neisseria meningitidis NHBA Proteins 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1